Myeloid neoplasms in inflammatory bowel disease: A case series and review of the literature

Abstract

Patients with inflammatory bowel disease (IBD) are exposed to chronic systemic inflammation and are at risk for secondary malignancies. Here we review the literature on the risk of myeloid neoplasms (MN) in IBD and present the disease profiles of patients at a single institution with IBD who later developed MN, comparing them to those in the literature. No IBD characteristic was found to associate with MN disease severity, including the previously-identified association between MNs and thiopurine exposure. Of the somatic mutations identified in out cohort's MN, mutations in TET2 were most prevalent, followed by FLT3-ITD, BCR-ABL, and NPM1 mutations.

Keywords

• Inflammatory bowel disease
• Myeloid neoplasm
• Thiopurine
• Clonal hematopoiesis
• Driver Mutation
• Case Series